Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. - Wikidata - awgldk - TriplyDB

Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome.

Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome.

http://www.wikidata.org/entity/Q36455711

about

Ribosome-inactivating proteins: from plant defense to tumor attack Interleukin-7 and interleukin-15 for cancer Toxin-based therapeutic approaches Disruption of the Putative Vascular Leak Peptide Sequence in the Stabilized Ricin Vaccine Candidate RTA1-33/44-198 NK cells in the tumor microenvironment.Advances in anticancer immunotoxin therapy Abrin triggers cell death by inactivating a thiol-specific antioxidant protein Circular DNA and DNA/RNA hybrid molecules as scaffolds for ricin inhibitor design Transition state analogues rescue ribosomes from saporin-L1 ribosome inactivating protein.Ricinus communis agglutinin I leads to rapid down-regulation of VEGFR-2 and endothelial cell apoptosis in tumor blood vessels.Interleukin-2 alters distribution of CD144 (VE-cadherin) in endothelial cells.The first alpha helix of interleukin (IL)-2 folds as a homotetramer, acts as an agonist of the IL-2 receptor beta chain, and induces lymphokine-activated killer cells Chronic systemic capillary leak syndrome. Report of a case and review of the literature.Intradermal administration of RiVax protects mice from mucosal and systemic ricin intoxication Photochemical internalization of tumor-targeted protein toxins.Resveratrol prevents endothelial cells injury in high-dose interleukin-2 therapy against melanoma A pilot clinical trial of a recombinant ricin vaccine in normal humans.Local treatment of brain tumors with targeted chimera cytotoxic proteins.Immunotoxins: a promising treatment modality for metastatic melanoma?Natural products synthesis: enabling tools to penetrate Nature's secrets of biogenesis and biomechanism.Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox Passive and active vaccination strategies to prevent ricin poisoning.Strong protection against ricin challenge induced by a novel modified ricin A-chain protein in mouse model.Immunotoxins constructed with chimeric, short-lived anti-CD22 monoclonal antibodies induce less vascular leak without loss of cytotoxicity.Ricin: current understanding and prospects for an antiricin vaccine.Collapse of the Microbiome, Emergence of the Pathobiome, and the Immunopathology of Sepsis.Antibody-cytotoxic agent conjugates for cancer therapy.Pilot phase IB clinical trial of an alhydrogel-adsorbed recombinant ricin vaccine.A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein.Potential use of IL-2/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease.Inhalation toxicology of ricin preparations: animal models, prophylactic and therapeutic approaches to protection.Novel CD7-specific nanobody-based immunotoxins potently enhanced apoptosis of CD7-positive malignant cells.Potential therapeutic applications of plant toxin-ricin in cancer: challenges and advances.High efficacy vasopermeability drug candidates identified by screening in an ex ovo chorioallantoic membrane model.Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency.Structural analysis and modeling of a synthetic interleukin-2 mimetic and its interleukin-2Rbeta2 receptor.Clinical targeting recombinant immunotoxins for cancer therapy Characterization of a re-engineered, mesothelin-targeted Pseudomonas exotoxin fusion protein for lung cancer therapy.Vascular targeting of anti-CD40 antibodies and IL-2 into autochthonous tumors enhances immunotherapy in mice.

P2860

Q26828935-73946427-BAFE-473C-9AA4-95676B0807F8 Q26830709-DB629E96-49B1-4286-B123-2A03CA0588E8 Q27013664-03F58659-09F8-4EBA-B67C-586F5BA075E9 Q27676062-7ECC6A2C-06D9-430B-B6EB-658C7064BA9D Q27692606-CED179BC-31CD-410B-A61C-DA75BA8E8A77 Q28085551-70B6FAEA-C6C4-4364-AF4B-BF7649C16584 Q28210339-118EB5C0-1ECE-4861-A1FA-538C620CE18B Q33281487-3B68FB97-BB8C-4ABE-B699-223E33DBA007 Q33504786-ADEF9B6C-A821-414B-A1EA-B4AE8D14595C Q33745257-DF84A24B-09F7-41AA-B67B-2711497E78D1 Q33774512-836383D3-31FB-4CC2-BC78-1B181A9AA520 Q33889058-46FFF48C-92BB-4F8C-9793-7DEBB37CCB2B Q33962246-F2EF07C8-109F-41D8-9FA6-5C4BF92AB749 Q34012394-B474262F-DE41-47F6-9B78-9BBBAEA70755 Q34068201-91E6DDCB-8F31-487C-91FE-1CEB40D9DC24 Q34245154-1DA1C936-6A5E-4CB2-A5DA-BC5264082AA0 Q34479216-1638A0C4-C610-4579-A835-CC8A8A57A575 Q34798727-29C09C35-8A3F-4741-9263-CB35391C2AA4 Q34986254-41D24766-3E54-4562-94BC-34C785831BAE Q35215703-F8205D38-9E6F-423D-A857-96E55A8266C9 Q35446035-29529715-7058-4AAC-98BF-9750928F1199 Q35459324-D433E70E-CAA8-4FE8-A4CB-2CCE83EBA334 Q35887201-8E6D083E-4B26-4EE6-9E2D-1FA9AEB19ED3 Q35918856-4132B529-D7A8-414D-B88A-A639D9618539 Q36124970-4519EF26-2460-4A11-9A6F-702A5CD29106 Q36252387-DC2D6F84-EA5E-4B50-A9B7-FF7BEB73F956 Q36316831-17BA8CEE-6BDA-4FC3-9230-59845F72B4F2 Q36362292-E591D86D-5478-463B-B4CA-46D6A2BDEBDE Q36536466-FCB75AC6-9D55-45DB-98BC-CF806C93B29F Q36552580-C1C0EDC1-BDC0-4E07-93A3-FF310C8F4354 Q36708311-1205A39D-0DD0-4CFC-817C-8A4C1DE031BF Q36905622-150C5850-A5FF-43C3-8D20-630F035CE29A Q37376200-ADAF45FD-11B4-421E-AC32-E66D2ECA619C Q38582930-484F1775-96DC-4A4F-9F20-93BC76720829 Q38824126-7565FEE5-403B-4086-9E92-DCF78FC86830 Q39203683-A3273263-9D3F-444F-A4AF-3B114EE735BC Q40658257-9AD89E5D-3033-431B-9044-EF5141035BA2 Q41149227-2B585D4B-4D36-4605-93AB-5CFEBF8D1F47 Q41934574-2538AF7F-7437-4756-AD82-77D2D338ECC2 Q43108657-227F3CF6-1D2D-4F0B-92D4-3B9701471F28

P2860

Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome.

http://www.wikidata.org/entity/Q36455711

description

1999 nî lūn-bûn

@nan

1999年の論文

@ja

1999年学术文章

@wuu

1999年学术文章

@zh-cn

1999年学术文章

@zh-hans

1999年学术文章

@zh-my

1999年学术文章

@zh-sg

1999年學術文章

@yue

1999年學術文章

@zh

1999年學術文章

@zh-hant

name

Evidence for a structural moti ...... iating vascular leak syndrome.

@ast

Evidence for a structural moti ...... iating vascular leak syndrome.

@en

type

label

Evidence for a structural moti ...... iating vascular leak syndrome.

@ast

Evidence for a structural moti ...... iating vascular leak syndrome.

@en

prefLabel

Evidence for a structural moti ...... iating vascular leak syndrome.

@ast

Evidence for a structural moti ...... iating vascular leak syndrome.

@en

P1433

Q36455711-F129D893-E8BF-4120-9F01-392981002FF7

P1476

Q36455711-94855198-2F8D-4640-998F-4BCEF021E8CF

P2093

Q36455711-17C9DF84-5FCB-45ED-9D9D-991868F6C583

Q36455711-206C0711-A9BE-4552-B065-7123F209B3A1

Q36455711-94812E50-CDBE-43AE-BBCD-CFC34387CF71

Q36455711-E9C4137A-07A9-4AC7-AABC-8FCD5D021D04

Q36455711-F1A9D994-7E1A-45BA-8A59-4430BE88215C

P2860

Q36455711-160552A7-3806-45E4-9E95-CE3FB6D815EA

Q36455711-3B548CF0-8BDD-4E9F-883E-8C5F73A3FEE5

Q36455711-3BF43C93-D896-4C1B-8B74-424AADF3C8C4

Q36455711-45F2CF10-D867-4A1F-9003-4F17EE71C9CB

Q36455711-48B731A5-3685-4B04-B931-FCE0677B2E55

Q36455711-4B879C32-C18D-48D0-91CA-74B2219ADCFF

Q36455711-4E85A11E-F767-4D80-8A7D-721DB8E51ABA

Q36455711-70462F97-0D9F-46F9-B692-964EC89F3144

Q36455711-77ECDB59-C164-4B1B-B403-3CC7C01C9134

Q36455711-79E29944-1673-459F-A6C3-3E4E897A127B

P304

Q36455711-29B2AE51-D532-40D3-87AF-A03C90EE9D55

P31

Q36455711-99BE7620-16A3-401C-B491-4D0DE8210F58

P356

Q36455711-7505CBA8-A345-433C-A56D-BE68F3981AD2

P407

Q36455711-4EA2F0C5-5EEE-4F06-8B21-48CC6E04D9B4

P433

Q36455711-FF335416-8D72-4E3E-861A-EED70D2DD646

P478

Q36455711-140FBA4B-D43B-4F2B-9B92-ABAF05838B30

P577

Q36455711-F6B5EC0E-ABA8-4E6E-9450-D669A39073F8

P5875

Q36455711-BC12113E-9AFC-4DED-94B4-E01B56D425A3

P698

Q36455711-E6F94CC9-D1DC-45F4-B0FD-CCCE7845D1A7

P921

Q36455711-00E9E056-ABAD-4431-9FE3-4CB296E95367

P932

Q36455711-45F1DD71-13A9-4197-9AB7-B9585BFB5B0B

P356

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Evidence for a structural moti ...... iating vascular leak syndrome.

@en

P2093

B E Gordon

http://www.w3.org/2001/XMLSchema#string

E S Vitetta

http://www.w3.org/2001/XMLSchema#string

J Rizo

http://www.w3.org/2001/XMLSchema#string

R Baluna

http://www.w3.org/2001/XMLSchema#string

V Ghetie

http://www.w3.org/2001/XMLSchema#string

P2860

The crystal structure of Pseudomonas aeruginosa exotoxin domain III with nicotinamide and AMP: conformational differences with the intact exotoxin

What have snakes taught us about integrins?

Clinical toxicity of interleukin-2.

Identification of specific residues of human interleukin 2 that affect binding to the 70-kDa subunit (p70) of the interleukin 2 receptor.

Structure of recombinant ricin A chain at 2.3 A

Rotavirus contains integrin ligand sequences and a disintegrin-like domain that are implicated in virus entry into cells.

The toxicity of chemically deglycosylated ricin A-chain in mice.

Ricin A-chain and ricin A-chain immunotoxins rapidly damage human endothelial cells: implications for vascular leak syndrome.

Vascular leak syndrome: a side effect of immunotherapy.

Viper venom disintegrins and related molecules.

P304

3957-3962

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.96.7.3957

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

96

http://www.w3.org/2001/XMLSchema#string

P577

1999-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

13194347

http://www.w3.org/2001/XMLSchema#string

P698

10097145

http://www.w3.org/2001/XMLSchema#string

P921

P932

22402

http://www.w3.org/2001/XMLSchema#string